These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 7829257)

  • 1. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
    Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic.
    Mezzanzanica D; Canevari S; Colnaghi MI
    Int J Clin Lab Res; 1991; 21(2):159-64. PubMed ID: 1815760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy.
    Lamers CH; van de Griend RJ; Braakman E; Ronteltap CP; Bénard J; Stoter G; Gratama JW; Bolhuis RL
    Int J Cancer; 1992 Jul; 51(6):973-9. PubMed ID: 1386349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1.
    Kroesen BJ; Nieken J; Sleijfer DT; Molema G; de Vries EG; Groen HJ; Helfrich W; The TH; Mulder NH; de Leij L
    Cancer Immunol Immunother; 1997; 45(3-4):203-6. PubMed ID: 9435874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model.
    Mezzanzanica D; Garrido MA; Neblock DS; Daddona PE; Andrew SM; Zurawski VR; Segal DM; Wunderlich JR
    Cancer Res; 1991 Oct; 51(20):5716-21. PubMed ID: 1833054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human antibody response to the intravenous and intraperitoneal administration of the F(ab')2 fragment of the OC125 murine monoclonal antibody.
    Maher VE; Drukman SJ; Kinders RJ; Hunter RE; Jennings J; Brigham C; Stevens S; Griffin TW
    J Immunother (1991); 1992 Jan; 11(1):56-66. PubMed ID: 1734949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
    Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
    Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.
    Bolhuis RL; Lamers CH; Goey SH; Eggermont AM; Trimbos JB; Stoter G; Lanzavecchia A; di Re E; Miotti S; Raspagliesi F
    Int J Cancer Suppl; 1992; 7():78-81. PubMed ID: 1428412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components.
    Mezzanzanica D; Canevari S; Ménard S; Pupa SM; Tagliabue E; Lanzavecchia A; Colnaghi MI
    Int J Cancer; 1988 Apr; 41(4):609-15. PubMed ID: 3258590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation.
    Jacobs N; Mazzoni A; Mezzanzanica D; Negri DR; Valota O; Colnaghi MI; Moutschen MP; Boniver J; Canevari S
    Cancer Immunol Immunother; 1997 Jul; 44(5):257-64. PubMed ID: 9247560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays.
    Buist MR; Kenemans P; van Kamp GJ; Haisma HJ
    Cancer Immunol Immunother; 1995 Jan; 40(1):24-30. PubMed ID: 7828165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: an effective in vivo antitumor strategy.
    Porter LE; Nelson H; Ethem Gecim I; Rice DC; Thibault C; Chapoval AI
    Cancer Immunol Immunother; 1997; 45(3-4):180-3. PubMed ID: 9435868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A; Stevenson GT; Glennie MJ
    J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
    Haagen IA; Geerars AJ; de Lau WB; Bast BJ; de Gast BC
    Blood; 1995 Jun; 85(11):3208-12. PubMed ID: 7538821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.
    Garrido MA; Valdayo MJ; Winkler DF; Titus JA; Hecht TT; Perez P; Segal DM; Wunderlich JR
    Cancer Res; 1990 Jul; 50(14):4227-32. PubMed ID: 2142014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further characterization of cytotoxic T cells generated by short-term culture of human peripheral blood lymphocytes with interleukin-2 and anti-CD3 mAb.
    Jacobs N; Greimers R; Mazzoni A; Trebak M; Schaaf-Lafontaine N; Boniver J; Moutschen MP
    Cancer Immunol Immunother; 1996 Jul; 42(6):369-75. PubMed ID: 8830741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome.
    Honeychurch J; Cruise A; Tutt AL; Glennie MJ
    Cancer Immunol Immunother; 1997; 45(3-4):171-3. PubMed ID: 9435866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity.
    van Dijk J; Zegveld ST; Fleuren GJ; Warnaar SO
    Int J Cancer; 1991 Jul; 48(5):738-43. PubMed ID: 1830033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes.
    Möller SA; Reisfeld RA
    Cancer Immunol Immunother; 1991; 33(4):210-6. PubMed ID: 1647871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
    Clark JI; Alpaugh RK; von Mehren M; Schultz J; Gralow JR; Cheever MA; Ring DB; Weiner LM
    Cancer Immunol Immunother; 1997 Jul; 44(5):265-72. PubMed ID: 9247561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.